Epilepsy in Leigh Syndrome With Mitochondrial DNA Mutations

Sunho Lee 1†, Ji-Hoon Na 1† and Young-Mock Lee 1,2*

1 Departments of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea, 2 Epilepsy Research Institute, Yonsei University College of Medicine, Seoul, South Korea

Background: Leigh syndrome is a mitochondrial cytopathy that presents as a neurodegenerative disease with apparent manifestation in the central nervous system. The aim of the present study was to describe its dominant neurological clinical features and analyze data related to epilepsy in Leigh syndrome accompanied by a mitochondrial DNA mutation.

Methods: Whole mitochondrial sequencing was performed on 125 patients clinically suspected of Leigh syndrome. Among them, 25 patients were identified to have mitochondrial DNA associated Leigh syndrome. Electroencephalography (EEG) findings, semiology, brain imaging findings, and biochemical results, were evaluated. We also compared brain magnetic resonance imaging findings and biochemical features in patients with Leigh syndrome based on the presence of epilepsy.

Results: Clinical seizures were observed in 14 out of 25 enrolled patients (56%), with focal seizures being the most common type (6/14, 42.8%). All patients were found to have slow and disorganized background neural activity while eight exhibited epileptic discharges on EEG. Mutations at base pairs 10,191 and 8,993 were revealed in a relatively larger number of patients of Leigh syndrome with epilepsy. The presence of gastrointestinal symptoms was significantly more frequent in the epilepsy group (P = 0.042). Diffuse cerebral atrophy was significantly increased (P = 0.042) and cortex signal abnormalities were also increased (P = 0.033) in the epilepsy group.

Conclusions: Patients with Leigh syndrome and mitochondrial DNA mutations had a high proportion of central nervous system comorbidities, though the prevalence of epilepsy in this population was not particularly high. Various types of seizure and EEG findings are common in those with Leigh syndrome. Future imaging studies involving more patients and proper mitochondrial DNA mutation analyses are needed to further evaluate the natural course of Leigh syndrome with epilepsy.

Keywords: epilepsy, mitochondria, Leigh syndrome, mitochondrial DNA, neuroimaging

INTRODUCTION

Leigh syndrome is a mitochondrial disorder, the diagnosis of which is defined by three key characteristics. First, symmetrical brain stem and/or basal ganglia dysfunction on imaging is required. Patients must also exhibit delayed intellectual and motor development, and/or elevated serum or cerebrospinal fluid (CSF) lactate levels on laboratory findings, indicating abnormal energy metabolism (1).
Mitochondrial disorders are associated with heterogeneous manifestations due to their involvement of multiple organs and physiological systems, though most affect the central nervous system (CNS) (2). Epilepsy is a typical phenotypic feature of mitochondrial disorders that affect the CNS (3). However, the prevalence of epilepsy is not equal among all patients with mitochondrial disorders. For instance, these rates vary among Leigh patients with West syndrome or epilepsy partialis continua (4–6), in whom the incidence of epilepsy is extremely low.

The present study aimed to describe the neurological manifestations of Leigh syndrome and, more specifically, analyze data related to epilepsy in Leigh syndrome confirmed by identification of a positive mitochondrial DNA mutation.

MATERIALS AND METHODS

Patients and Enrollment Criteria

We performed a retrospective review of the medical records including genetic and laboratory reports of 125 patients with Leigh syndrome who had been treated at Gangnam Severance Hospital. All of the patients had confirmed mitochondrial disease, per the criteria described by Bernier et al. (7). Additionally, patients had confirmed diagnoses of Leigh syndrome (LS), as confirmed by Rahman et al. (8). These criteria include a progressive neurodegenerative disease with motor and intellectual developmental delays, signs and symptoms of brainstem and/or basal ganglia dysfunction on neuroimaging, and elevated serum or CSF fluid lactate levels. Whole mitochondrial sequencing was carried out on 125 clinically diagnosed with Leigh syndrome. Among them, 27 patients have mitochondrial DNA mutations but we excluded two patients whose mitochondrial DNA mutations were of unidentified type. Twenty-five patients were genetically confirmed to have mitochondrial DNA-associated Leigh syndrome and were included in the study.

Evaluation of Mitochondrial Disease and Leigh Syndrome

Diagnostic evaluations of patients with LS were performed. These included laboratory assessments of serum lactate levels and neuroimaging. The severity of serum lactic acidosis was defined as normal, mild (≥2-fold normal reference value), moderate (≥3-fold normal reference value). The neuroimaging modality used was brain MRI, while MR spectroscopy was used to identify a lactate peak in degenerated lesions of the brain.

Histological reports from biopsies of skeletal muscle taken from 23 patients were reviewed. Using light and/or electron microscopy, the presence of meacona or pleoconia, or ragged red fibers were used as specific findings to indicate mitochondrial disease, while a preponderance of atrophic type 1 fibers were defined as non-specific findings (7). As mitochondrial chain complex (MRC) defects are defined as those below 20% of control levels (9), we also set our reduction of residual enzyme activity more strictly to <10% of controls. DNA from all patients were assessed for mitochondrial DNA (mtDNA) mutations based on a molecular sequencing analysis.

Epilepsy Related Analysis

Factors related to epilepsy, including seizure semiology and the diagnostic evaluation tool developed by the International League Against Epilepsy (ILAE) (10) classification as well as EEG findings. Additional assessments of participant treatment responses were based on numbers of anti-epileptic drugs and seizure frequency.

Subgrouping and Statistical Analyses

Patients were divided into two groups based on their epilepsy status. All analyses were performed using SPSS version 21.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics include medians and ranges. Chi-squared distribution, the Mann-Whitney U-test, and the Pearson exact test were used to evaluate differences between groups. A $P < 0.05$ was considered to indicate statistical significance.

RESULTS

Clinical Characteristics

In total, 25 patients were enrolled in the present study, including 10 males and 15 females. A family history of mitochondrial disease was noted in 4 of the 25 patients. The most common first onset symptom was developmental delay (40.0%), followed by seizures (12.0%). The mean age of first symptom onset was approximately 1 year (range: 0.15–9.88 years) and all patients were diagnosed within 9 years of first symptom onset. The mean duration of follow-up in our institute was over 5 years. All patients were involved in neuromuscular system treatment (100%), while over half underwent ophthalmic treatment. Developmental delays were evident alongside neuromuscular symptoms in 68.0% of patients, while seizures were evident in 32.0% (Table 1).

Neuroimaging and Diagnostic Evaluation of Leigh Syndrome

Increased signal intensity in the basal ganglia (92.0%) and brainstem (76.0%) on MRI were both observed, with over a half (84%) of patients exhibiting a lactate peak on plasma MR spectroscopy. An additional 20 patients exhibited mildly increased serum lactate levels. Electron microscopic changes were identified, including pleoconia (34.8%) or meacona (26.0%). Mitochondrial respiratory chain complex 4 defects were also detected in 12 patients, and complex 1 defects in 11 patients (Tables 2, 3).

Mitochondrial DNA Mutations in Leigh Syndrome

We analyzed 16,500 base pairs of mitochondrial DNA using direct sequencing to confirm the most reliable mutations related to Leigh syndrome based on established genetic reports. Mutations at base pairs 10,191, 13,513, and 8,993 were revealed in relatively larger number of patients suffering Leigh syndrome with epilepsy (Table 4).
### Table 1: Comparison of clinical characteristics in Leigh syndrome participants with and without epilepsy.

| General characteristics | Total (N = 25) | Epilepsy (N = 14) | Without Epilepsy (N = 11) | P-value |
|-------------------------|----------------|------------------|--------------------------|---------|
| Sex (male:female)       | 10 (40.0%):15 (60.0%) | 7 (50.0%):7 (50.0%) | 3 (27.3%):8 (72.7%) | 0.414   |
| Family history          |                |                  |                          |         |
| Mitochondrial disease   | 4/25 (16.0%)   | 3/14 (21.4%)     | 1/11 (9.1%)              | 0.604   |
| Other neurologic disease| 3/25 (12.0%)   | 1/14 (7.1%)      | 2/11 (18.2%)             | 0.565   |
| None                    | 18/25 (72.0%)  | 10/14 (71.4%)    | 8/11 (72.7%)             | 0.649   |
| Epilepsy                | 0/25 (0.0%)    | 0/14 (0.0%)      | 0/11 (0.0%)              | –       |
| First onset symptoms    |                |                  |                          |         |
| Developmental regression| 10/25 (40.0%)  | 7/14 (50.0%)     | 3/11 (27.3%)             | 0.414   |
| Ptosis                  | 4/25 (16.0%)   | 2/14 (14.3%)     | 2/11 (18.2%)             | 0.604   |
| Ataxia                  | 4/25 (16.0%)   | 1/14 (7.1%)      | 3/11 (27.3%)             | 0.288   |
| Respiratory difficulty  | 4/25 (16.0%)   | 1/14 (7.1%)      | 3/11 (27.3%)             | 0.288   |
| Seizure                 | 3/25 (12.0%)   | 3/14 (21.4%)     | 0/11 (0.0%)              | 0.230   |
| Age of 1st symptoms (years) | 1.44 (0.15–9.88) | 1.46 (0.16–4.65) | 1.26 (0.50–9.88) | 0.827   |
| Age of muscle biopsy (years) | 2.02 (0.52–20.33) | 1.88 (0.52–7.33) | 3.90 (1.05–20.33) | 0.101   |
| Interval from 1st symptom to confirmative diagnosis of LS (months) | 7.87 (0.90–136.00) | 7.85 (0.90–64.17) | 9.07 (1.27–136.00) | 0.488   |
| Interval for follow up (years) | 5.73 (0.74–10.94) | 5.9 (0.74–10.56) | 4.6 (0.74–10.98) | 0.477   |
| Additional system involvement |                |                  |                          |         |
| Neuromuscular           | 25/25 (100.0%) | 14/14 (100.0%)   | 11/11 (100.0%)           | –       |
| Ophthalmic              | 15/25 (60.0%)  | 10/14 (71.4%)    | 5/11 (45.5%)             | 0.241   |
| Respiratory             | 9/25 (36.0%)   | 7/14 (50.0%)     | 2/11 (18.2%)             | 0.208   |
| Cardiologic             | 8/25 (32.0%)   | 4/14 (28.6%)     | 4/11 (36.4%)             | 0.504   |
| Gastrointestinal        | 8/25 (32.0%)   | 7/14 (50.0%)     | 1/11 (9.1%)              | 0.042   |
| Endocrinologic          | 7/25 (28.0%)   | 5/14 (35.7%)     | 2/11 (18.2%)             | 0.407   |
| Renal                   | 4/25 (16.0%)   | 3/14 (21.4%)     | 1/11 (9.1%)              | 0.604   |
| Auditory                | 3/25 (12.0%)   | 3/14 (21.4%)     | 0/11 (0.0%)              | 0.230   |
| Urologic                | 3/25 (12.0%)   | 2/14 (14.3%)     | 1/11 (9.1%)              | 0.593   |
| Skeletal                | 3/25 (12.0%)   | 3/14 (21.4%)     | 0/11 (0.0%)              | 0.230   |
| Neuromuscular symptoms  |                |                  |                          |         |
| Developmental delay     | 17/25 (68.0%)  | 9/14 (64.3%)     | 8/11 (72.7%)             | 0.496   |
| Seizure                 | 8/25 (32.0%)   | 8/14 (57.1%)     | 0/11 (0.0%)              | 0.003   |
| Dystonia                | 7/25 (28.0%)   | 5/14 (35.7%)     | 2/11 (18.2%)             | 0.407   |
| Ataxia                  | 5/25 (20.0%)   | 2/14 (14.3%)     | 3/11 (27.3%)             | 0.623   |
| Spasticity              | 5/25 (20.0%)   | 4/14 (28.6%)     | 1/11 (9.1%)              | 0.341   |
| Dysarthria              | 3/25 (12.0%)   | 1/14 (7.1%)      | 2/11 (18.2%)             | 0.565   |
| Psychomotor delay       | 2/25 (8.0%)    | 0/14 (0.0%)      | 2/11 (18.2%)             | 0.183   |
| Muscle weakness         | 1/25 (4.0%)    | 1/14 (7.1%)      | 0/11 (0.0%)              | 0.560   |

**Epilepsy in Leigh Syndrome**

A total of 14 patients with Leigh syndrome in the present study were confirmed to also have epilepsy (Table 5). The mean age of seizure onset among these individuals was approximately 2 years. During the initial stage, their seizure frequency reported was about seven times per month. We found that six patients (42.8%) had a focal seizure locus while 5 (35.7%) had generalized seizure semiology. Complex partial seizure was the most common (3/14) (21.4%) type of focal seizure observed. As for generalized seizure types, myoclonic seizure, tonic seizure, atonic seizure, and tonic-clinic seizure were observed with relatively even prevalence among patients. In addition, two patients showed partial seizure with secondary generalization and one patient had unclassified epileptic seizures.

All patients showed slow and disorganized background neural activity while eight exhibited epileptic discharges on EEG. Among them, five patients had focal sharp or spike waves, accounting for 35.7% of the total. In this study, none of the patients with Leigh syndrome experiencing epilepsy had an episode of status epilepticus.

A total of 12 patients (85.7%) were taking anti-epileptic drugs at the time. Eight patients were taking only one AED (57.1%). However, four patients failed to control their seizure within 1 year of their initial treatment and went on to taking two or more types of AEDs. During an average follow-up period of 5.7 years, eight patients were taking one AED at the time of the last visit, accounting for 57.1% of the total. However, the number of patients taking three or more multiple AEDs was four (28.6%).
TABLE 2 | Comparison of neuroimaging findings in Leigh syndrome participants with and without epilepsy.

| Neuroimaging findings   | Total (N = 25) | Epilepsy (N = 14) | Without Epilepsy (N = 11) | P-value |
|-------------------------|---------------|-------------------|---------------------------|---------|
| MRI ABNORMALITIES       |               |                   |                           |         |
| Basal ganglia           | 23/25 (82.0%) | 14/14 (100.0%)    | 9/11 (81.8%)              | 0.183   |
| Brain stem              | 19/25 (76.0%) | 12/14 (85.7%)     | 7/11 (63.6%)              | 0.350   |
| Cerebellar atrophy      | 15/25 (60.0%) | 9/14 (63.3%)      | 6/11 (54.5%)              | 0.697   |
| Thalamus                | 12/25 (40.0%) | 9/14 (63.3%)      | 3/11 (27.3%)              | 0.111   |
| Diffuse cerebral atrophy| 11/25 (44.0%) | 9/14 (63.3%)      | 2/11 (18.2%)              | 0.042   |
| Cortex                  | 9/25 (30.0%)  | 8/14 (57.1%)      | 1/11 (9.1%)               | 0.033   |
| White matter            | 7/25 (25.0%)  | 6/14 (42.9%)      | 1/11 (9.1%)               | 0.09    |
| MR SPECTROSCOPY         |               |                   |                           |         |
| Lactate peak            | 15/22 (68.2%) | 8/13 (61.5%)      | 7/9 (77.8%)               | 0.648   |

MRI, magnetic resonance; MRI, magnetic resonance imaging.

TABLE 3 | Comparison of diagnostic evaluation between Leigh syndrome participants with and without epilepsy.

| Diagnostic evaluation | Total | Epilepsy (N = 14) | Without epilepsy (N = 11) | P-value |
|-----------------------|-------|-------------------|---------------------------|---------|
| LACTIC ACIDOYSIS (N = 25) |      |                   |                           |         |
| Within normal range   | 4/25 (16.0%) | 1/14 (7.1%)      | 3/11 (27.3%)              | 0.288   |
| Mildly increased (<2-fold) | 20/25 (80.0%) | 12/14 (85.7%)    | 8/11 (72.7%)              | 0.623   |
| Moderated increased (2–3-fold) | 1/25 (4.0%)  | 1/14 (7.1%)      | 0/11 (0.0%)               | 0.560   |
| Severe increased (>3-fold) | 0/25 (0.0%)   | 0/14 (0.0%)      | 0/11 (0.0%)               | –       |
| MUSCLE BIOPSY OBTAINED (N = 23) |     |                   |                           |         |
| Specific findings for mitochondrial disease | 4/23 (17.4%) | 2/13 (15.4%)    | 2/10 (20.0%)              | 0.596   |
| Non-specific findings | 2/23 (8.7%)  | 1/13 (7.7%)      | 1/10 (10.0%)              | 0.692   |
| Electron microscopic changes |       |                   |                           |         |
| Pleoconia              | 8/23 (34.8%) | 4/13 (30.4%)     | 4/10 (40.0%)              | 0.685   |
| Megaconia              | 6/23 (26.0%) | 4/13 (30.8%)     | 2/10 (20.0%)              | 0.660   |
| MRC enzyme assay       |       |                   |                           |         |
| Complex IV defect      | 12/23 (52.2%) | 6/13 (46.2%)    | 6/10 (60.0%)              | 0.680   |
| Complex I defect       | 11/23 (47.8%) | 7/13 (53.8%)    | 4/10 (40.0%)              | 0.680   |

MRC, mitochondrial chain complex.

Two patients were on the ketogenic diet and did not fully respond to multiple AEDs.

After we started the AED, we summarized the treatment effects of the patients. Six patients became seizure free and three patients achieved decreased seizure frequency. There were two patients with no change of seizure frequency and one patient suffered increased seizure frequency. However, over the entire follow-up period, seizure free status was observed in 8 out of 14 patients.

**Comparison of Those With Leigh Syndrome With and Without Comorbid Epilepsy**

We divided our participants, all of whom had Leigh syndrome, into two groups based on their epilepsy status groups and presence of mtDNA mutations. We found no statistically significant differences in the clinical characteristics of the two groups, except for their gastrointestinal system symptoms and seizure history (Table 1). The presence of gastrointestinal symptoms was significantly higher in the epilepsy group (50.0 vs. 9.1%, P = 0.042).

A comparison of MRI findings between the two groups revealed that diffuse cerebral atrophy was significantly increased with epilepsy (64.3 vs. 18.2%, P = 0.042). Cortex signal abnormalities with epilepsy were also increased (57.1 vs. 9.1%, P = 0.033). Abnormal signals in other areas on MRI and lactate peaks on MR spectroscopy did not differ between the epilepsy and non-epilepsy groups. Additionally, there were no statistically significant differences in lactic acidosis, muscle biopsy findings, mitochondrial chain complex defects, or mitochondrial DNA mutation types between the two groups.

**DISCUSSION**

Epilepsy is one of the most significant clinical manifestations of mitochondrial disorders. Mitochondrial chain impairments are often caused by neuronal mitochondrial DNA damage, which is an aspect of epileptogenesis (11). The incidence of epilepsy
in mitochondrial encephalopathy presents ranges widely, though most studies report 35–61% (11–13). In our study, 14 out of 25 patients had epilepsy, which corresponds to a morbidity of 56%. This was within the range of the existing reference but on the higher side. The prevalence of epilepsy in individuals with Leigh syndrome ranges sporadically, but is generally high, similar to that of mitochondrial disorder in individuals with epilepsy (3, 5, 14). Other mitochondrial disorders accompanying epilepsy, such as Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) and Myoclonic epilepsy with ragged red fibers (MERRF), were reported by Lee et al. to have similar prevalence (4, 15). Despite this, seizure is not included as a diagnostic feature of Leigh syndrome. However, epilepsies in individuals with Leigh syndrome are often noted to be relatively high, possibly due to the confusion of seizures with other neuromuscular symptoms such as dystonia or spasticity. The present study indicates that the incidence of epilepsy in Leigh syndrome patients falls within previously established ranges. Given this, we conclude that the incidence of epilepsy may differ from that of subtypes of mitochondrial disorders, as there is cortical dysfunction in each which may limit the accuracy of a purely syndromic diagnosis.

Cortical abnormalities revealed via neuroimaging (e.g., MRI) are often used to indicate epilepsy (16, 17). Similarly, ubiquinone deficiencies, MELAS, POLG (polymerase subunit gamma) mutation, and Kearns-Sayre Syndrome are all associated with various lesions and brain MRI abnormalities, including alterations in the cerebral cortex, seizure, or stroke-like episodes (18). However, most Leigh patients also exhibit abnormalities in the brain stem or basal ganglia, with rare cases exhibiting cortical lesion on MRI (19, 20). In the present study, the proportion of patients with Leigh syndrome revealed to have some cortical abnormalities on MRI was over half, especially in those with epilepsy, indicating that cortical changes on neuroimaging may reflect impending epilepsy in Leigh syndrome. Mitochondrial disorders often feature critical dysfunctions in the CNS, which stem from the high-energy demands of the CNS, resulting in diffuse or focal brain tissue atrophy (9, 21). The present study reveals a relatively high proportion of cerebral atrophy among those with Leigh syndrome and significantly increased rates in those with epilepsy. It is possible that epilepsy’s high metabolic cost may lead to accelerated central nervous dysfunction with mitochondrial dysfunction, ultimately leading to the deterioration that occurs in the natural course of Leigh syndrome with comorbid epilepsy. Sofou et al. found that multiple factors, including epilepsy and birth defects, resulted in exacerbated Leigh syndrome. Typically, patients with Leigh syndrome are thought to live 2 or 3 years beyond first symptom onset, with those with late onset Leigh syndrome living up to 20 years of age. However, in most patients, deterioration begins to accelerate at ~20 months of age (22, 23). In patients with Leigh syndrome with comorbid epilepsy, timely evaluation including neuroimaging is particularly critical, as their symptoms may worsen and have deteriorating prognosis. Based on the results that diffuse atrophy is more associated with Leigh syndrome with epilepsy, it can serve as a good imaging indicator of disease progression. So, we strongly suggest that neuroimaging may provide critical clues about the disease course and may be helpful for the detection of epilepsies among patients with Leigh syndrome.

Mitochondrial dysfunction leads to various, non-specific clinical phenotypes including gastrointestinal symptoms such as dysphagia, malnutrition, gastroparesis, and constipation (8). Gastrointestinal dysmotility may be caused by decreased mitochondrial proliferation and thus leads to marked atrophy of the external layer of the muscular propria (24). Some studies of mitochondrial neuro-gastro-intestinal encephalopathy (MNGIE) have also reported its association with non-specific neurologic symptoms, such as ophthalmoplegia and ptosis or panayiotopoulos epilepsy (25, 26). In their analysis of patients with MELAS, de Laat et al. found that 20% experienced dysphagia and constipation while 40% experienced gastroparesis, which often contributes to nutrition absorption failures and malnutrition (27). Gastrointestinal symptoms may be due to either central or peripheral neuropathy, though epilepsies such as panayiotopoulos epilepsy or the aura that accompanies a focal epilepsy are often misdiagnosed as celiac disease or other gastrointestinal diseases (28) and thus the connection between these symptoms and epilepsies remains poorly understood. For instance, Yeh et al. reported a high risk of gastrointestinal hemorrhage in epilepsy patients (29), though this

### TABLE 4 | Comparison of mtDNA mutations between Leigh syndrome participants with and without epilepsy.

| mtDNA mutations | Total (N = 25) | Epilepsy (N = 14) | Without epilepsy (N = 11) | P-value |
|-----------------|---------------|------------------|---------------------------|---------|
| 10191 T>C       | 4/25 (16.0%)  | 4/14 (28.6%)     | 0/11 (0.0%)               | 0.105   |
| 13513 G>A       | 4/25 (16.0%)  | 1/14 (7.1%)      | 3/11 (27.3%)              | 0.288   |
| 8993 T>G        | 4/25 (16.0%)  | 2/14 (14.3%)     | 2/11 (18.2%)              | 0.604   |
| 8993 T>C        | 3/25 (12.0%)  | 1/14 (7.1%)      | 2/11 (18.2%)              | 0.565   |
| 9176 T>C        | 3/25 (12.0%)  | 1/14 (7.1%)      | 2/11 (18.2%)              | 0.565   |
| 3697 G>A        | 2/25 (8.0%)   | 1/14 (7.1%)      | 1/11 (9.1%)               | 0.697   |
| 10158 T>C       | 1/25 (4.0%)   | 1/14 (7.1%)      | 0/11 (0.0%)               | 0.560   |
| 10744 A>G       | 1/25 (4.0%)   | 1/14 (7.1%)      | 0/11 (0.0%)               | 0.560   |
| 11777 C>A       | 1/25 (4.0%)   | 1/14 (7.1%)      | 0/11 (0.0%)               | 0.560   |
| 14459 G>A       | 1/25 (4.0%)   | 0/14 (0.0%)      | 1/11 (9.1%)               | 0.440   |
| 9185 T>C        | 1/25 (4.0%)   | 0/14 (0.0%)      | 1/11 (9.1%)               | 0.440   |
TABLE 5 | Characteristics of epilepsy in Leigh syndrome patients (total N = 14).

| SEIZURE TYPE                  | Count (%) |
|-------------------------------|-----------|
| **Age of first seizure (years)** | 2.10 (0.12–4.92)* |
| **Initial seizure frequency/month** | 7.14 (1–24)* |
| **SEIZURE TYPE**              |           |
| Focal seizures                | 6/14 (42.8%) |
| Simple partial without motor signs | 1/14 (7.1%) |
| Simple partial with motor signs | 2/14 (14.3%) |
| Complex partial                | 3/14 (21.4%) |
| Generalized seizures           | 5/14 (35.7%) |
| Myoclonic seizures             | 2/14 (14.3%) |
| Tonic seizures                 | 1/14 (7.1%) |
| Atonic seizures                | 1/14 (7.1%) |
| Tonic-clonic seizures          | 1/14 (7.1%) |
| Partial seizure with secondary generalization | 2/14 (14.3%) |
| Unclassified epileptic seizures | 1/14 (7.1%) |
| Mixed type of seizures         | 4/14 (28.6%) |

**ELECTROENCEPHALOGRAPHY**

| Electrographic seizure          | Count (%) |
|---------------------------------|-----------|
| Generalized seizure             | 1/14 (7.1%) |
| Focal seizure                   | 2/14 (14.3%) |
| Numbers of status epileptics    | 0/14 (0%) |

**TREATMENT OPTIONS**

| With antiepileptic drugs (AEDs) | Count (%) |
|----------------------------------|-----------|
| Levetiracetam                    | 4/14 (28.6%) |
| Lamotrigine                      | 3/14 (21.4%) |
| Oxcarbamazepine                  | 3/14 (21.4%) |
| Zonisamide                       | 3/14 (21.4%) |
| Topiramate                       | 2/14 (14.3%) |
| Phenytoin                        | 1/14 (7.1%) |
| Carbamazepine                    | 1/14 (7.1%) |

| Numbers of initial treatment     | Count (%) |
|----------------------------------|-----------|
| No AED                           | 2/14 (14.3%) |
| 1 AED                            | 8/14 (57.1%) |
| 2 AEDs                           | 3/14 (21.4%) |
| 3 AEDs                           | 1/14 (7.1%) |

| Numbers of last visit            | Count (%) |
|----------------------------------|-----------|
| No AED                           | 2/14 (14.3%) |
| 1 AED                            | 6/14 (42.9%) |
| 2 AEDs                           | 2/14 (14.3%) |
| 3 AEDs                           | 2/14 (14.3%) |
| >3 AEDs                          | 2/14 (14.3%) |

**RESPONSE TO AEDs AFTER 1 YEAR**

| Count (%) |
|-----------|
| Seizure free | 6/14 (42.8%) |
| Decreased seizure frequency | 3/14 (21.4%) |

Continued...
with generalized epilepsy and EEG spikes while MELAS presents with focal or generalized seizures and focal or multifocal EEG spikes (15, 33). Mitochondrial disorder patients assessed in the present study exhibited slow and disorganized background EEG signals, though they also exhibited multifocal or focal spikes depending on the mitochondrial disorder subtype. Other aspects of epilepsy also differ between mitochondrial disease cases. For instance, Lee et al. compared reductions in seizure frequency with more than 1 year of anti-epileptic treatment and found that 13% of syndromic mitochondrial disease patients experienced 50–75% decreases while 26% of nonsyndromic mitochondrial patients experienced decreases of <25% (34). By comparison, the results of the present study reveal that 42.8% of Leigh syndrome patients were seizure free after 1 year and that 57.1% of patients were seizure free upon their last clinic visit. These results indicate that prevalence of seizure semiology on EEG and the effects of anti-epileptic treatment may differ depending on the particular subtype of mitochondrial disorder (35).

While our data reveal some interesting trends with regard to Leigh syndrome with mtDNA mutations, the study’s sample size was not large enough to parse particular subtype differences, posing a significant limitation to the present study. In this study, we investigated the association regarding epilepsy in patients with mtDNA associated Leigh syndrome only. Nevertheless, a study of epilepsy in Leigh syndrome with nuclear DNA (nDNA) mutations is further needed. A comparative study of the epilepsy pattern between Leigh syndrome with mtDNA mutation and with nDNA mutation would be worthwhile for the better understanding of Leigh syndrome.

CONCLUSION

Epilepsy is a significant neurologic manifestation of Leigh syndrome. In the present study, we found an increase in the prevalence of gastrointestinal symptoms among those with Leigh syndrome and epilepsy (vs. without epilepsy), potentially due to the high energy demands associated with epilepsy. We also found that acute imaging changes may indicate an increased risk for epilepsy in individuals with Leigh syndrome, suggesting that imaging should be conducted within 2 years of diagnosis to determine the syndrome’s natural course. Additionally, various types of epilepsy and differences in seizure semiology on EEG findings were also found to be associated with different mitochondrial disorders. The optimal and precise diagnosis of these disorders may lead to the increased accuracy of their diagnosis and improved treatments for epilepsy in mitochondrial disorders. Further studies that include the various subtypes of mitochondrial disorders and the use of larger samples are needed to develop improved diagnosis and treatment strategies. Given our findings, we contend that specialists in mitochondrial disorders should create individualized treatment plans and assess the disorder’s natural course and prognosis in each case that they treat. As the science on these disorders moves forward, so too will its treatment.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of the Institutional Review Board of Gangnam Severance Hospital, Yonsei University College of Medicine with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Institutional Review Board of Gangnam Severance Hospital, Yonsei University College of Medicine.

AUTHOR CONTRIBUTIONS

Y-ML conceptualized and designed the study, coordinated and supervised data collection, and critically reviewed and revised the manuscript. SL and J-HN designed the data collection instruments, collected data, carried out the initial analyses, drafted the initial manuscript and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for the content of the work.

FUNDING

This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health&Welfare, Republic of Korea (grant number: 2016-31-0041 & 2017-31-0038).

ACKNOWLEDGMENTS

The authors are grateful to all staff members, doctors, and statistical consultants who were involved in this study.
abnormalities. Ann Neurol. (1996) 39:343–51. doi: 10.1002/ana.410390311
9. Saneto RP, Friedman SD, Shaw DW. Neuroimaging of mitochondrial disease. Mitochondrion. (2008) 8:396–413. doi: 10.1016/j.mito.2008.05.003
10. Fisher RS, Cross JH, D’Souza C, French JA, Haut SR, Higurashi N, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. (2017) 58:531–42. doi: 10.1111/epi.13671
11. Kunz WS. The role of mitochondria in epileptogenesis. Curr Opin Neurol. (2002) 15:179–84. doi: 10.1097/00019052-200204000-00009
12. Khurana DS, Salganicoff L, Melvin JJ, Hobdell EF, Valencia I, Hardison HH, et al. Epilepsy and respiratory chain defects in children with mitochondrial encephalopathies. Neuropediatrics. (2008) 39:8–13. doi: 10.1055/s-2008-1076737
13. Lee YM, Kang HC, Lee JS, Kim SH, Kim EY, Lee SK, et al. Mitochondrial disease. Mitochondrion. (2008) 8:1255–6. doi: 10.1016/j.bbabio.2008.11.014
14. Leshinsky-Silver E, Shuvalov R, Inbar S, Cohen S, Lev D, Lerman-Sagie T. Juvenile Leigh syndrome, optic atrophy, ataxia, dystonia, and epilepsy due to T14487C mutation in the mtDNA-ND6 gene: a mitochondrial syndrome presenting from birth to adolescence. J Child Neurol. (2011) 26:476–81. doi: 10.1177/0883073810384815
15. Lee HN, Eom SY, Kim SH, Kang HC, Lee JS, Kim HD, et al. Epilepsy characteristics and clinical outcome in patients with Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS). Pediatr Neurol. (2018) 83:137–9. doi: 10.1016/j.pediatrneurol.2018.03.034
16. Leshinsky-Silver E, Shuvalov R, Inbar S, Cohen S, Lev D, Lerman-Sagie T. Juvenile Leigh syndrome, optic atrophy, ataxia, dystonia, and epilepsy due to T14487C mutation in the mtDNA-ND6 gene: a mitochondrial syndrome presenting from birth to adolescence. J Child Neurol. (2011) 26:476–81. doi: 10.1177/0883073810384815
17. Trichard M, Léautaud A, Bednarek N, Mac-Caby G, Cardini-Poirier S, Motte J, et al. Neuroimaging in pediatric epilepsy. Arch Pediatr. (2012) 19:509–22. doi: 10.1016/j.arcped.2012.02.022
18. Bricout M, Grévent D, Lebre AS, Rio M, Desguerre I, De Lonlay P, et al. Brain imaging in mitochondrial respiratory chain deficiency: combination of brain MRI features as a useful tool for genotype/phenotype correlations. J Med Genet. (2014) 51:429–35. doi: 10.1136/jmedgenet-2013-102256
19. Davis PC, Hoffman JC, Braun IF, Ahmann P, Krawiecki N. MR of Leigh’s disease (subacute necrotizing encephalomyelopathy). AJNR Am J Neuroradiol. (1987) 8:71–5.
20. Bonfante E, Koenig MK, Adejumobi RB, Perinjelil V, Riascos RF. The neuroimaging of Leigh syndrome: case series and review of the literature. Pediatr Radiol. (2016) 46:443–51. doi: 10.1007/s00247-015-3523-5
21. Sofou K, Steneryd K, Wiklund LM, Tulinius M, Darin N. MRI of the brain in childhood-onset mitochondrial disorders with central nervous system involvement. Mitochondrion. (2013) 13:364–71. doi: 10.1016/j.mito.2013.04.008
22. Sofou K, De Coo IE, Isohanni P, Ostergaard E, Naess K, De Meirleir L, et al. A multicenter study on Leigh syndrome: disease course and predictors of survival. Orphanet J Rare Dis. (2014) 9:52. doi: 10.1186/1750-1172-9-52
23. Naess K, Freyer C, Bruhn H, Wibom R, Malm G, Nennesmo I, et al. Mitochondrial mutations are a common cause of severe disease phenotypes in children with Leigh syndrome. Biochim Biophys Acta. (2009) 1787:484–90. doi: 10.1016/j.bbapai.2008.11.014
24. Chapman TP, Hadley G, Fratter C, Cullen SN, Bax BE, Bain MD, et al. Unexplained gastrointestinal symptoms: think mitochondrial disease. Dig Liver Dis. (2014) 46:1–8. doi: 10.1016/j.dld.2013.04.008
25. D’Angelo R, Rinaldi R, Carelli V, Boschetti E, Caporali L, Capristo M, et al. ITA-MNGIE: an Italian regional and national survey for mitochondrial neuro-gastro-intestinal encephalomyopathy. Neuro prec. (2016) 37:1149–51. doi: 10.1007/s10072-016-2552-7
26. Hirano M, Silvestri G, Blake DM, Lombe A, Minetti C, Bonilla E, et al. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology. (1994) 44:721–7. doi: 10.1212/WNL.44.4.721
27. de Laat P, Zweers HE, Knuitj S, Smeitink JA, Waten GP, Janssen MC. Dysphagia, malnutrition and gastrointestinal problems in patients with mitochondrial disease caused by the m3243A>G mutation. Neth J Med. (2015) 73:30–4.
28. Caribonari G, Tonti P, Pisa VD, Franzoni E, Cordelli DM. Pediatric epilepsies misdiagnosed as gastrointestinal disorders. Epilepsy Behav. (2018) 83:137–9. doi: 10.1016/j.yebeh.2018.03.034
29. Yue CC, Wang HH, Chou YC, Hu SJ, Chou WH, Chen TL, et al. High risk of gastrointestinal hemorrhage in patients with epilepsy: a nationwide cohort study. Mayo Clin Proc. (2013) 88:1091–8. doi: 10.1016/j.mayocp.2013.06.024
30. Crepin S, Godet B, Chassain B, Preux PM, Desport JC. Malnutrition and epilepsy: a two-way relationship. Clin Nutr. (2009) 28:219–25. doi: 10.1016/j.clnu.2009.03.010
31. Schwartzkroin PA, Baraban SC, Hochman DW. Osmolality, ionic flux, and changes in brain excitability. Epilepsy Res. (1998) 32:275–85. doi: 10.1016/S0920-1211(98)00058-8
32. Finsterer J, Zarrourk Mahjoub S. Mitochondrial epilepsy in pediatric and adult patients. Acta Neurol Scand. (2013) 128:141–52. doi: 10.1111/ane.12122
33. Brackmann F, Abicht A, Ahling U, Schröder R, Trollmann R. Classical MERRF phenotype associated with mitochondrial tRNA(Leu)(m.3243A>G) mutation. Eur J Pediatr. (2012) 171:859–62. doi: 10.1007/s00431-011-1662-8
34. Lee HF, Chi CS, Tsai CR, Chen CH. Epileptic seizures in infants and children with mitochondrial diseases. Pediatr Neurol. (2011) 45:169–74. doi: 10.1016/j.pediatrneurol.2011.04.008
35. Chevallier JA, Von Allmen GK, Koenig MK. Seizure semiology and EEG findings in mitochondrial diseases. Epilepsia. (2014) 55:707–12. doi: 10.1111/epi.12570

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Lee, Na and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.